B. Gill-Barman

Comparing the utility of FDG PET-CT and contrast-enhanced CT in patients with oesophagogastric adenocarcinoma treated with neoadjuvant chemotherapy

Abstract Background 2-deoxy-2[ 18 F]fluoro-D-glucose positron emission tomography-CT (FDG PET-CT) is established in staging oesophagogastric adenocarcinoma. It has an emerging role in assessing response to neoadjuvant chemotherapy (NACT) but its benefits over contrast-enhanced CT...